Glenmark introduces DCGI-approved type-2 diabetes drug in India

Indian pharmaceutical company, Glenmark has reportedly introduced a new FDC (fixed-dose combination) of a broadly used Dipeptidyl Peptidase 4 (DPP4) inhibitor, Teneligliptin, with Pioglitazone for people who have type 2 diabetes.

The drug, which is launched under the Zita Plus Pio brand name, will increase the availability of the quality drug for managing diabetes.

Currently, Zita Plus Pio is the only available combination of Glitazone and DPP4 brands in India.

The FDC of Pioglitazone+Teneligliptin is approved by the Drug Controller General of India (DCGI) and will aid in advancing the glycemic control in the adult population with insulin struggle, those whose diabetes is unable to be controlled by metformin, and those who need the addition of Pioglitazone and Teneliglitptin as different drugs.

Glenmark Pharmaceuticals’ Head and Group VP – India Formulations, Alok Malik, while commenting on the development, said that diabetes is a major area of focus for Glenmark, a leader in offering novel options of treatment for diabetic patients in India.

The firm is delighted to unveil this novel Zita Plus Pio, which is said to be the very first kind of drug available in the country, offering an affordable and top-class option for treating adult diabetic patients.

According to the IDF (International Diabetes Federation), the pervasiveness of diabetes in India is about 75 million adults, which is estimated to rise to 125 million (around 70% increase) by 2045. Of these, around 77% of patients have uncontrolled diabetes.

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals is a pharmaceutical company that has spread its global presence across generics, specialty, and OTC businesses. It emphasizes the major therapeutic areas of dermatology, respiratory, and oncology.

Recently, the drug maker combined net profit dropped 3.4% to Rs 239.75 crore on a 13.9% increase in net sales to Rs 3,141.47 crore in Q3 FY22 compared to Q3 FY21. Its stock also fell 1.52% to Rs 436.70 on the BSE.

Source Credit - https://www.business-standard.com/article/news-cm/glenmark-pharma-launches-fdc-for-type-2-diabetes-in-india-122042500220_1.html